Extraintestinal manifestations of inflammatory bowel disease

Current Gastroenterology Reports

Volumn 10, Issue 6, 2008, Pages 597-605

  Williams, Horace ^b   Walker, David ^b   Orchard, Timothy R ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CALCIUM; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLCHICINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; ETANERCEPT; HLA B27 ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; POTASSIUM IODIDE; PROBIOTIC AGENT; RISEDRONIC ACID; ROFECOXIB; SALAZOSULFAPYRIDINE; URSODEOXYCHOLIC ACID; VALDECOXIB;

ANKYLOSING SPONDYLITIS; ARTHRITIS; BALLOON DILATATION; BILE DUCT CARCINOMA; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOMA; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; ERYTHEMA NODOSUM; ETHNIC DIFFERENCE; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INFECTION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LUNG DISEASE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MORBIDITY; NEUROLOGIC DISEASE; OSTEOPOROSIS; PATHOGENESIS; PATIENT MONITORING; PHENOTYPE; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PYODERMA GANGRENOSUM; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; SCLERITIS; STENT; T CELL LYMPHOMA; ULCERATIVE COLITIS; UVEITIS;

HUMANS; INFLAMMATORY BOWEL DISEASES; PHENOTYPE;

EID: 60749113903     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0108-6     Document Type: Review

References (83)

1. Ricart E, Panaccione R, Loftus EV, et al.: Autoimmune disorders and extraintestinal manifestations in first degree familial and sporadic inflammatory bowel disease: A case-control study. Inflamm Bowel Dis 2004, 10:207-214.
2. Greenstein AJ, Janowitz HD, Sachar DB: The extraintestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine (Baltimore) 1976, 55:401-412.
3. Bernstein CN, Wajda A, Blanchard JF: The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study. Gastroenterology 2005, 129:827-836.
4. Cappell MS, Turkieh A: Chronic pericarditis and pericardial tamponade associated with ulcerative colitis. Dig Dis Sci 2008, 53:149-154.
5. Watanabe T: Parotitis and acute pancreatitis in a patient with ulcerative colitis. Eur J Pediatr 2008, 167:945.
6. Mahid SS, Mulhall AM, Gholson RD, et al.: Inflammatory bowel disease and African Americans: A systematic review. Inflamm Bowel Dis 2008, 14:960-967.
7. Nguyen GC, Torres EA, Regueiro M, et al.: Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: Characterization of a large North American cohort. Am J Gastroenterol 2006, 101:1012-1023.
8. Basu D, Lopez I, Kulkarni A, Sellin JH: Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005, 100:2254-2261.
9. Rodriguez VE, Costas PJ, Vazquez M, et al.: Prevalence of spondyloarthropathy in Puerto Rican patients with inflammatory bowel disease. Ethn Dis 2008, 18(Suppl 2):225-229.
10. Lanna CC, Ferrari M, Rocha SL, et al.: A cross-sectional study of 130 Brazilian patients with Crohn's disease and ulcerative colitis: Analysis of articular and ophthalmologic manifestations. Clin Rheumatol 2008, 27:503-509.
11. Orchard TR, Thiyagaraja S, Welsh KI, et al.: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118:274-278.
12. Orchard TR, Chua CN, Ahmad T, et al.: Uveitis and erythema nodosum in inflammatory bowel disease: Clinical features and the role of HLA genes. Gastroenterology 2002, 123:714-718.
13. Roussomoustakaki M, Satsangi J, Welsh K, et al.: Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997, 112:1845-1853.
14. Williams HRT, Sato H, Welsh KI, et al.: Clinical and genetic associations of pyoderma gangrenosum in patients with inflammatory bowel disease: Evidence for a shared predisposition to extraintestinal manifestations [abstract]. Gut 2007, 56(Suppl III): A21. Presented at United European Gastroenterology Week. Paris; October 2007.
15. Peeters H, Vander Cruyssen B, Laukens D, et al.: Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004, 63:1131-1134.
16. Peeters H, Vander Cruyssen B, Mielants H, et al.: Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol 2008, 23:132-137.
17. Mielants H, Veys EM, De Vos M, et al.: The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995, 22:2266-2272.
18. Elewaut D, De Keyser F, Van Den Bosch F, et al.: Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998, 25:1932-1937.
19. Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history. Gut 1998, 42:387-391.
20. Travis SP, Stange EF, Lémann M, et al.; European Crohn's and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn's disease: Current management. Gut 2006, 55(Suppl 1):i16-i35.
21. Fornaciari G, Salvarini C, Beltrami M, et al.: Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001, 15:399-403.
22. Steer S, Jones H, Hibbert J, Kondeatis, et al.: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003, 30:518-522.
23. Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, et al.: Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978, 37:33-35.
24. Brown MA, Pile KD, Kennedy LG, et al.: HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996, 55:268-270.
25. Orchard T, Holt H, Bradley L, et al.: Prevalence of sacroiliitis in Crohn's disease, and its correlation with clinical, radiologic and genotypic parameters [abstract]. Gastroenterology 2002, 122(Suppl 4):W1298.
26. Thjodleifsson B, Geirsson AJ, Björnsson S, Bjarnason I: A common genetic background for inflammatory bowel disease and ankylosing spondylitis: A genealogic study in Iceland. Arthritis Rheum 2007, 56:2633-2639.
27. Rahman P, Inman RD, Gladman DD, et al.: Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008, 58:1020-1025.
28. Duerr RH, Taylor KD, Brant SR, et al.: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
29. Cargill M, Schrodi SJ, Chang M, et al.: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-290.
30. Felder JB, Korelitz BI, Rajapakse R, et al.: Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol 2000, 95:1949-1954.
31. Evans JM, McMahon AD, Murray FE, et al.: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619-622.
32. Takeuchi K, Smale S, Premshand P, et al.: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:196-202.
33. Bonner GF, Fakhri A, Vennamaneni SR: A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:751-757.
34. Dougados M, Dijkmans B, Khan M, et al.: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002, 61:40-50.
35. Chen J, Liu C, Lin J: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006, CD004524.
36. Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: A Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325-2329.
37. Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondyloarthropathy. A randomised, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627.
38. Taggart A, Gardiner P, McEvoy F, et al.: Which is the active moiety of sulfasalazine in ankylosing spondylitis? Arthritis Rheum 1996, 39:1400-1405.
39. van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA: Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol 2003, 30:1558-1560.
40. Thomson GT, Thomson BR, Thomson KS, Ducharme JS: Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000, 27:714-718.
41. Dekker-Saeys BJ, Dijkmans BA, Tytgat GN: Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): An open trial. J Rheumatol 2000, 27:723-726.
42. Karimi O, Peña AS: Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. Rev Esp Enferm Dig 2005, 97:570-574.
43. Levine JB, Lukawski-Trubish D: Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Amer 1995, 24:633-646.
44. Generini S, Giacomelli R, Fedi R, et al.: Infliximab in spondyloarthropathy associated with Crohn's disease: An open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664-1669.
45. Braun J, Baraliakos X, Listing J, et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007, 57:639-647.
46. Timani S, Mutasim DF: Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008, 26:265-273.
47. Veloso FT, Carvalho J, Magro F: Immune-related systemic manifestations of inflammatory bowel disease: A prospective study of 792 patients. J Clin Gastroenterol 1996, 23:29-34.
48. Trost LB, McDonnell JK: Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005, 81:580-585.
49. Tavarela VSloso F: Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl 4):50-53.
50. Callen JP: Pyoderma gangrenosum. Lancet 1998, 351:581-585.
51. Brooklyn T, Dunnill G, Probert C: Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006, 333:181-184.
52. Chow RK, Ho VC: Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996, 34:1047-1060.
53. Brooklyn TN, Dunnill MG, Shetty A, et al.: Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut 2006, 55:505-509.
54. Girardin M, Waschke KA, Seidman EG: A case of acute loss of vision as the presenting symptom of Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:695-698.
55. Mintz R, Feller ER, Bahr RL, Shah SA: Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:135-139.
56. Loftus EV: Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 2004, 6:506-513.
57. Hale S, Lightman S: Anti-TNF therapies in the treatment of acute and chronic uveitis. Cytokine 2006, 33:231-237.
58. Moff SL, Kamel IR, Eustace J, et al.: Diagnosis of primary sclerosing cholangitis: A blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006, 64:219-223.
59. MacFaul GR, Chapman RW: Sclerosing cholangitis. Curr Opinion Gastroenterol 2004, 20:275-280.
60. Talwalkar JA, Angulo P, Johnson CD, et al.: Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39-45.
61. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
62. Mitchell SA, Bansi DA, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
63. Olsson R, Boberg KM, de Muckadell OS, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-1472.
64. Cullen SN,CChapman RW: Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 21:933-948.
65. Brandsaeter B, Isoniemi H, Broome U, et al.: Liver transplantation for primary sclerosing cholangitis: Predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815-822.
66. Eaden JA, Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002, 51:v10-v12.
67. Wolf JM, Rybicki LA, Lashner BA: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783-788.
68. Pardi DS, Loftus EV, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
69. Rodríguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK: Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol 2007, 13:6156-6165.
70. Lamb EJ, Wong T, Smith DJ, et al.: Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1895-1902.
71. Card T, West J, Hubbard R, Logan RF: Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004,53: 251-255.
72. Vestergaard P, Mosekilde L: Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: A nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1-10.
73. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841
74. American Gastroenterological Association: Medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791-794.
75. Boonen S, Rizzoli R, Meunier PJ, et al.: The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: A consensus report. Osteoporos Int 2004, 15:511-519.
76. Henderson S, Hoffman N, Prince RA: Double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119-123.
77. Raj AA, Birring SS, Green R, et al.: Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med 2008, 102:780-785.
78. Izzedine H, Simon J, Piette AM, et al.: Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 2002, 123:1436-1440.
79. Marcus SB, Brown JB, Melin-Aldana H, Strople JA: Tubulointerstitial nephritis: An extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr 2008, 46:338-341.
80. Archimandritis AJ, Weetch MS: Kidney granuloma in Crohn's disease. BMJ 1993, 307:540-541.
81. Baumer P, Brocard JF, Kohn W, et al.: Severe chronic interstitial nephritis associated with Crohn's disease, but not with mesalazine? Gastroenterol Clin Biol 1999, 23:1400-1402.
82. Unal A, Sipahioglu MH, Akgun H, et al.: Crohn's disease complicated by granulomatous interstitial nephritis, choroidal neovascularization, and central retinal vein occlusion. Intern Med 2008, 47:103-107.
83. Scheid R, Teich N: Neurologic manifestations of ulcerative colitis. Eur J Neurol 2007, 14:483-493.